Neose Announces Phase II Renal Trial of NE-180
Neose Technologies has started dosing in its Phase II clinical trial of NE-180 in renal patients.
NE-180 is a GlycoPEGylated erythropoietin being developed for the treatment of anemia in adult cancer patients with nonmyeloid malignancies receiving chemotherapy and for the treatment of anemia associated with chronic kidney disease.
The Phase II renal trial is designed as an open-label, sequential, ascending dose study to evaluate the safety, tolerability and dose response of NE-180 administered subcutaneously at fixed doses every four weeks.
The company said it expects to enroll a maximum of 60 patients with anemia associated with chronic renal failure.